Support

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Sunday, 08 August 2021 11:19

Paul Fogarty

Written by
Sunday, 08 August 2021 11:19

Annette Maree McWilliams

Written by
Dr McWilliams is a Consultant Respiratory Physician at Fiona Stanley Hospital and Clinical Associate Professor at the University of Western Australia in Perth, Australia. She also holds the role of Clinical Lead of the Thoracic Tumour Collaborative of Western Australia. She has been an investigator on the PanCanadian Early Detection of Lung Cancer Study and is currently an investigator on the International LungScreen Trial. The focus of her clinical and research work over the last 20 years has been the early detection, diagnosis, staging and treatment of lung cancer.
Sunday, 08 August 2021 11:19

Fraser Brims

Written by
Sunday, 08 August 2021 11:19

Henry Marshall

Written by
Sunday, 08 August 2021 11:19

Alain Tremblay

Written by
Sunday, 08 August 2021 11:19

Mamta Ruparel

Written by
Sunday, 08 August 2021 11:19

Renelle Myers

Written by
Sunday, 08 August 2021 11:19

Martin C Tammemagi

Written by
Dr. Tammemägi is Professor Emeritus (Epidemiology) in the Department of Health Sciences at Brock University and is Provincial Scientific Lead for Ontario Health – Cancer Care Ontario’s Lung Screening Program. He has been a co-investigator and remains an active analyst in the U.S. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), the U.S. National Lung Screening Trial (NLST), the Pan-Canadian Early Detection of Lung Cancer Study, and the International Lung Screening Trial. He is an active associate member of the U.S. National Cancer Institute sponsored Cancer Intervention and Surveillance Modeling Network (CISNET) Lung Group. Dr. Tammemägi has a strong interest in cancer epidemiology with special interests in lung cancer screening and cancer risk prediction modelling. He has developed several widely validated and adopted lung cancer risk prediction models. Tammemägi’s PLCOm2012 lung cancer risk prediction model has been validated in over 20 studies in more than 7 countries and is now being implement for selection of individuals for lung cancer screening in several jurisdictions (Tammemagi MC, et al. Selection criteria for lung-cancer screening. The New England journal of medicine. 2013;368(8):728-36.). Tammemägi ’s PanCan (syn. Brock model) Nodule Malignancy Probability Model has been extensively validated and accepted into clinical practice and has been recommended for selected use by the American College of Radiology’s LungRADS system and by the British Thoracic Society Guidelines for the Investigation and Management of Pulmonary Nodules (McWilliams A, Tammemagi MC, et al. Probability of cancer in pulmonary nodules detected on first screening CT. The New England journal of medicine. 2013;369(10):910-9.). In addition, Dr. Tammemägi is involved in several studies of lung cancer screening disparities and finding more effective ways to screen Blacks in the U.S. and Indigenous peoples in multiple countries around the world.
Sunday, 08 August 2021 11:18

Lawson Eng

Written by
Dr Lawson Eng, MD, SM, FRCPC is a Medical Oncologist at the Princess Margaret Cancer Centre and incoming Assistant Professor in the Department of Medicine, University of Toronto in Toronto, Canada. His clinical practice focuses on lung, gastrointestinal and head and neck cancers. His research interests are in cancer survivorship and supportive care with a focus on health behaviours (in particular, tobacco control) in cancer survivors, patient-reported outcomes, real-world population-level outcomes research and health services research. He serves on the Cancer Care Ontario – Smoking Cessation Research and Knowledge Translation Committee, MASCC Survivorship Working Group, and the International Association of the Study of Lung Cancer (IASLC) - Tobacco Control Committee. To date, he has published over 45 manuscripts in oncology and has over 120 abstract presentations at international meetings. He is well-recognized for his research having received multiple American Society of Clinical Oncology (ASCO) Merit Awards and Novartis Oncology Young Canadian Investigator Awards, an ASCO Young Investigator Award (2020), a MASCC Young Investigator Award (2018), the 2019 Canadian Association of Medical Oncology (CAMO) Fellowship Award and both a Canadian Institutes of Health Research (CIHR) Publication Prize and Fellowship Award. He has also served as an invited speaker for tobacco control in cancer care at multiple national and international meetings.
Page 219 of 371